Mechanisms that explain the contraceptive action of progestin implants for women

Contraception

Volumn 65, Issue 1, 2002, Pages 21-27

  Croxatto, Horacio B ^a  

^a Instituto Chileno de Medicina Reproductiva   (Chile)

Author keywords

Contraceptive implant; Etonogestrel; Levonorgestrel; Mode of action; Nestorone; Nomegestrol acetate

Indexed keywords

ELCOMETRINE; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; NOMEGESTROL ACETATE;

ARTICLE; CLINICAL TRIAL; CONTRACEPTION; DRUG CAPSULE; DRUG EFFECT; DRUG EFFICACY; DRUG IMPLANT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RELEASE; ENDOMETRIUM; FERTILIZATION; GAMETE; GENITAL SYSTEM; GONADOTROPIN RELEASE; HUMAN; HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS; OVARY FUNCTION; OVULATION; REPRODUCTION; SIDE EFFECT; SPERMATOZOON; TARGET CELL; UTERINE CERVIX MUCOSA; UTERINE CERVIX MUCUS;

CERVIX MUCUS; CONTRACEPTIVE DEVICES, FEMALE; DRUG IMPLANTS; ENDOMETRIUM; FEMALE; HUMANS; OVARY; PROGESTERONE CONGENERS;

EID: 0036183140     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(01)00294-3     Document Type: Article

References (48)

1. Progestin implants for female contraception
2. Plasma progesterone levels during long-term treatment with levonorgestrel Silastic implants
3. Ovarian endocrine function through five years of continuous treatment with Norplant subdermal contraceptive implants
4. Estradiol plasma levels during long-term treatment with Norplant subdermal implants
5. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants
6. Ovarian function during use of subdermal implants releasing low doses of levonorgestrel
7. Characteristics of ovarian follicular development in Norplant users
8. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels
9. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implant users with regular menses
10. Bleeding pattern, outcome of accidental pregnancies, and levonorgestrel plasma levels associated with method failure in Norplant implants users
11. Regulation of mammalian oocyte maturation
12. Oocyte-granulosa cell interactions
13. Ovulation
14. Ovulation 2: Control of the resumption of meiotic maturation in mammalian oocytes
15. Ovulation
16. Effects of varying doses of HCG on the evolution of preovulatory rabbit follicles and oocytes
17. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function
18. Follicle growth curves and hormonal patterns in patients with the luteinized unruptured follicle syndrome
19. Ovulatory disturbances in patients with luteal insufficiency
20. The pattern of the luteinizing hormone surge in spontaneous cycles is related to the probability of conception
21. Relationship between midcycle luteinizing hormone surge quality and oocyte fertilization
22. Gamete transport
23. The cervical cycle
24. Daily postcoital tests in the conception cycle during treatment of anovulatory women with human gonadotropins
25. A new quantitative test of sperm penetration into cervical mucus
26. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants
27. Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro
28. Timing of onset of contraceptive effectiveness in Norplant implant users. 1. Changes in cervical mucus
29. Histopathology of the endometrium during continuous use of Levonorgestrel
30. Endometrial changes in women using hormonal contraceptives for periods up to ten years
31. The pharmacodynamics and efficacy of Implanon. An overview of the data
32. Vaginal bleeding disturbances and implantable contraceptives
33. Norplant implants: Mechanism of contraceptive action
34. Release characteristics, ovarian activity, and menstrual bleeding pattern with a single implant releasing 3-ketodesogestrel
35. Clinical trial with Nestorone subdermal contraceptive implants
36. Use of a single implant of Elcometrine (ST-1435), a nonorally active progestin, as a long-acting contraceptive for postpartum women
37. Pituitary and ovarian function during contraception with one subcutaneous implant releasing a progestin, ST 1435
38. Contraception with subdermal ST-1435 capsules: Side effects, endocrine profiles, and liver function related to different lengths of capsules
39. Concentration-dependent mechanisms of ovulation inhibition by the progestin ST-1435
40. A contraceptive subdermal implant releasing the progestin ST-1435: Ovarian function, bleeding, bleeding patterns, and side effects
41. Contraception with subdermal implants releasing the progestin ST-1435: A dose-finding study
42. Ovarian function during use of Nestorone subdermal implants
43. One year contraception with a single subdermal implant containing Nomegestrol acetate (Uniplant)
44. Effects of a single contraceptive implant containing nomegestrol acetate on ovarian function and cervical mucus production during two years
45. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant)
46. Neuroendocrine mechanism of anovulation in users of contraceptive subdermal implant of nomegestrol acetate (Uniplant)
47. Temporal relationship between Uniplant insertion and changes in cervical mucus